Creative Medical Technology Holdings, Inc. (CELZ)

NASDAQ: CELZ · USD

$0.71

+0.02 (+3.2%)· Recorded snapshot

Market cap	4.7M
Revenue (ttm)	3K
Net income (ttm)	-6M
EPS (ttm)	-$1.95
Shares out	6.6M
Volume	90,323
Beta	1.90

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3K
Net income (ttm): -6M
EPS (ttm): -$1.95
Market cap: 4.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-77.9

P25 n/aP50 n/aP75 n/a

ROIC-50.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CELZ indicators

Market & fundamental data

Available fields

189

Groups with data

Currency

USD

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001187953
Company name	Creative Medical Technology Holdings, Inc.
Country	United States
Country code	US
CUSIP number	22529Y408
Earnings date	2026-11-10
Earnings time	amc
Employees	4
Employees change	0
Employees growth	0%
Enterprise value	$-4.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1998
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US22529Y4089
Last 10-K release date	2026-03-20
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split date	2023-06-12
Last stock split type	Reverse
Market cap	$4.7M
Market cap category	Nano-Cap
Next earnings date	2026-11-10
Options	No
Price	$0.71
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	CELZ
U.S. state	Arizona
Website	https://www.creativemedicaltechnology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-274.34%
FCF / EV yield	140.73%
FCF yield	-127.43%
P/B ratio	0.52x
P/S ratio	1,543.76x
Price / tangible book value	0.56x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	66.87%
Operating margin	-208,004.4%
Pretax margin	-201,285.83%
Profit per employee	$-1.5M
Revenue per employee	$750
ROA	-47.32%
ROA (5Y)	-38.5%
ROCE	-71.9%
ROE	-77.88%
ROIC	-50.21%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	3
Gross profit growth	-44.28%
Gross profit growth 3Y	-66.19%
Gross profit growth 5Y	-51.45%
Net income growth years	0
Revenue growth	-50%
Revenue growth 3Y	-65.59%
Revenue growth 5Y	-50.84%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$113,781
EBIT	$-6.2M
EBITDA	$-6.1M
EPS	$-1.95
FCF per share	$-0.90
Financing cash flow	$8.3M
Free cash flow	$-5.9M
Gross profit	$2,006
Investing cash flow	$-225,500
Net cash flow	$2.2M
Net income	$-6M
Operating income	$-6.2M
Revenue	$3,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-4.46
Book value per share	$1.33
Debt / equity	0
Long-term assets	$358,740
Long-term liabilities	$0
Net cash (debt)	$8.8M
Net cash / market cap	190.55%
Net cash growth	35.15%
Net debt / equity	-1.02
Piotroski F-Score	2
Shareholders' equity	$8.7M
Tangible book value	$8.3M
Tangible book value per share	$1.28
Total assets	$9.4M
Total cash	$8.8M
Total debt	$14,194
Total liabilities	$698,595
WACC	14.68%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$9M
Current liabilities	$698,595
Current ratio	12.91
Net working capital	$-504,603
Quick ratio	12.65
Working capital	$8.3M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-61.5%
Dividend yield	0%
Shareholder yield	-61.5%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-100%
10Y return CAGR	-73.29%
10Y total return	-100%
150-day SMA	$1.48
1D price change	3.16%
1M price change	-31.33%
1M total return	-31.33%
1W price change	-4.73%
1W total return	-4.73%
1Y price change	-86.25%
1Y return CAGR	-86.27%
1Y total return	-86.25%
20-day SMA	$0.81
200-day SMA	$1.59
3M price change	-10.84%
3M total return	-10.84%
3Y price change	-83.85%
3Y return CAGR	-45.54%
3Y total return	-83.85%
50-day SMA	$0.95
50-day SMA vs 200-day SMA	50under200
52-week high	$6.25
52-week high date	2025-10-28
52-week low	$0.62
52-week low date	2026-08-03
5Y price change	-99.04%
5Y return CAGR	-60.55%
5Y total return	-99.04%
6M price change	-68.98%
6M total return	-68.98%
All-time high	$525,013.13
All-time high date	2017-04-05
All-time low	$0.62
All-time low date	2026-08-03
Average true range (ATR)	$0.07
Average volume	107.6K
Beta (1Y)	5
Beta (2Y)	1.65
Beta (5Y)	1.9
Change from 52-week high	-88.61%
Change from 52-week low	14.84%
Change from all-time high	-100%
Change from all-time low	14.08%
Change from open	0%
Day's gap	3.16%
Dollar volume	$64,310
High price	$0.71
Low price	$0.71
Monthly RSI	33.24
Open price	$0.71
Premarket change	-0.01%
Premarket close	$0.69
Premarket price	$0.69
Previous close	$0.69
Price vs 150-day SMA	-52.18%
Price vs 20-day SMA	-12.31%
Price vs 200-day SMA	-55.49%
Price vs 50-day SMA	-25.67%
Relative volume	0.85
RSI	35.27
Sharpe ratio	-0.74
Sharpe ratio (3Y)	-0.03
Sharpe ratio (5Y)	-0.09
Sortino ratio	-1.22
Sortino ratio (3Y)	0.01
Sortino ratio (5Y)	-0.11
Volume	90.3K
Weekly RSI	33.99
YTD price change	-63.91%
YTD total return	-63.91%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6.6M
Float percentage	99.46%
Shares change (QoQ)	0%
Shares change (YoY)	61.5%
Shares held by insiders	0.19%
Shares held by institutions	9.14%
Shares outstanding	6.6M
Short % of float	1.25%
Short % of shares	1.24%
Short ratio	0.1 days

Deeper analysis on CELZ

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CELZ report

Is a complete CELZ research report available?

No complete published report is available for Creative Medical Technology Holdings, Inc. (CELZ) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Creative Medical Technology Holdings, Inc. (CELZ)

Price

Financial snapshot

Fair-value bridge

Latest news · CELZ

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CELZ indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CELZ

Frequently asked questions